Aclarion, Inc.

Oct 22, 2026

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Aclarion announced a study validating Nociscan, showing it identified painful lumbar discs with up to 87% agreement with invasive discography. The non-invasive scan offers a cost-effective alternative, sparing patients from needles and recovery time. The authors suggest Nociscan may eventually replace discography in selected patients, enhancing its adoption among physicians.

Oct 20, 2026

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Aclarion, Inc. reported significant growth in scan volume, achieving an 85% increase year-over-year in Q3 2026. The company is advancing its CLARITY clinical trial, now enrolling at eleven sites with updated criteria to improve recruitment. Additionally, the European Spine Journal published supportive data for its technology, enhancing its clinical evidence base. Aclarion maintains a strong financial position with $14.2 million in cash.

Oct 13, 2026

ACONConferences/Events

Aclarion to Present at the 20th Annual LD Micro Main Event

Aclarion (NASDAQ: ACON) will present at the 20th Annual LD Micro Main Event on October 20, 2026, at 11:30 AM PT. CEO Brent Ness will represent the company during the presentation. The event will take place at the Luxe Sunset Boulevard Hotel in Los Angeles, featuring over 100 public companies and networking opportunities for investors.

Oct 8, 2026

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Aclarion has updated the enrollment criteria for its CLARITY clinical trial to better reflect real-world chronic low back pain patients. The revisions have been approved by most active sites, which is anticipated to accelerate patient enrollment. The company will provide an update on enrollment levels and the timeline for the initial readout by year-end, while maintaining the overall trial duration.

Sep 29, 2026

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Aclarion, Inc. has announced that NYU Langone Health has joined its CLARITY trial network, which is focused on improving surgical outcomes for chronic low back pain using Nociscan. This prospective, randomized clinical trial aims to evaluate the effectiveness of Nociscan in identifying painful discs. The trial is set to enroll 300 patients across multiple sites, enhancing the clinical research landscape for spine surgery.

Aug 20, 2026

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion, Inc. has announced the University of Arizona College of Medicine – Phoenix as a new site for its CLARITY trial, which evaluates the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain. The trial now includes ten active sites and aims to establish Nociscan as a standard of care. The study will assess 300 patients and expects to release interim results in Q4 2026.

Aug 12, 2026

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion received a USPTO Notice of Allowance for a patent improving MR Spectroscopy precision in its Nociscan workflow. The innovation reduces scan time and improves result consistency across imaging centers. This approval extends Aclarion's intellectual property portfolio to over 65 issued and pending patents worldwide.

Aug 4, 2026

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Aclarion, Inc. has announced the availability of its Nociscan platform at Goodman Campbell Brain & Spine, marking the first site in Indiana to offer this technology. Nociscan utilizes Magnetic Resonance Spectroscopy to provide insights into chronic low back pain, distinguishing between painful and nonpainful discs. The partnership aims to enhance patient care and reflects Aclarion's expansion efforts.

Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

Aclarion, Inc. reported significant progress in the first half of 2026, including a 141% increase in scan volume year-over-year. The company has launched a Market Access Program to enhance insurance coverage for its Nociscan technology. Additionally, Aclarion is advancing its CLARITY trial and has strengthened its intellectual property portfolio with a new AI patent. The company maintains a robust financial position with $16.3 million in cash and no debt.

Jul 21, 2026

ACONConferences/Events

Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice

Aclarion presented two abstracts at the ASPN Annual Meeting, showcasing the clinical utility of Nociscan in treating chronic low back pain. One study highlighted the integration of Magnetic Resonance Spectroscopy (MRS) into clinical practice, while the other detailed a successful case study of basivertebral nerve ablation guided by Nociscan. The findings suggest significant advancements in real-world applications of this technology.

Jul 7, 2026

Aclarion Announces Texas Spine Care Center as New CLARITY Site

Aclarion, Inc. has announced the Texas Spine Care Center as a new site for its CLARITY trial, which evaluates the Nociscan technology for chronic low back pain. The trial aims to demonstrate Nociscan's effectiveness in improving surgical outcomes. Texas Spine Care's commitment to identifying pain sources aligns with Nociscan's capabilities. The study will involve 300 patients and aims for initial results by Q4 2026.

Jun 10, 2026

ACONConferences/Events

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Aclarion, Inc. will present at the Planet MicroCap Las Vegas 2026 on June 17, 2026. The company is experiencing significant growth in its Nociscan platform, which aids in diagnosing chronic low back pain. Key highlights include an anticipated interim readout from the CLARITY trial and a $2.5 million share repurchase program. The presentation will be hosted by Executive Chairman Jeff Thramann.

Jun 9, 2026

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion has partnered with PRIA Healthcare to enhance the reimbursement and commercial adoption of its AI-powered Nociscan platform for chronic low back pain. This Market Access Program aims to replicate the success of reimbursement wins in the UK, facilitating patient access and supporting healthcare providers in assessing the platform's clinical value. The collaboration is expected to streamline the reimbursement process and generate insights into payer dynamics.

Jun 8, 2026

▼ -5.9%on this newsshared move

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Aclarion, Inc. has rejected an unsolicited acquisition proposal from Echo Lake Capital. The Board believes the offer of $4.00 per share significantly undervalues the company and its strategic assets. They assert that the proposal would allow Echo Lake to acquire Aclarion's cash and assets at a discount, harming other shareholders.

Jun 8, 2026

▼ -5.9%on this newsshared move

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Aclarion, Inc. announced that stockholders approved all proposals at its 2026 Annual Meeting. Key approvals included the election of new board members and an amendment to the equity incentive plan. CEO Brent Ness highlighted significant growth in Nociscan scan volumes and progress in insurance coverage and reimbursement strategies.

Jun 3, 2026

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion, Inc. has partnered with the Institute of Neuro Innovation to enhance the availability of its Nociscan platform in the Los Angeles area. This collaboration aims to generate real-world evidence by comparing Nociscan's chemical biomarker data with SPECT-CT bone metabolic information. The partnership supports Aclarion's growth strategy while providing critical insights for treating chronic low back pain.

Jun 1, 2026

Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study

Aclarion's Nociscan technology was featured in a study revealing immune-related factors in back pain. The research identified elevated propionic acid levels in Modic type 1 patients, suggesting immune activation. This could enhance the understanding of pain origins and expand Nociscan's applications beyond surgical decision support. The findings may lead to personalized treatment strategies.

May 28, 2026

▼ -6.7%on this newsshared move

Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal

Aclarion, Inc. responded to Echo Lake Capital's unsolicited acquisition proposal of $4.00 per share. The Board is committed to evaluating this offer while emphasizing their strategic priorities and recent share repurchase program. They also addressed misleading assertions in Echo Lake's communication regarding governance.

May 7, 2026

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion announced the inclusion of Lanman Spinal Neurosurgery in its CLARITY trial, aimed at improving surgical outcomes for chronic low back pain. The trial evaluates Nociscan's effectiveness in identifying pain-generating discs. The company expects to release early interim results in Q4 2026, marking a significant step in expanding the trial.

May 6, 2026